Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
Authors
Keywords
Immunotherapy, Translational medical research, Tumour biomarkers, Tumour microenvironment
Journal
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-09-21
DOI
10.1016/j.ejca.2021.08.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-Cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
- (2021) Ali H. Zaidi et al. Oncotarget
- An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
- (2020) Katharina Reinhard et al. SCIENCE
- Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
- (2020) Kevin J Harrington et al. CLINICAL CANCER RESEARCH
- Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
- (2020) Gregory V. Goldmacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
- (2020) Iván Márquez-Rodas et al. Science Translational Medicine
- How Many Cohorts Should be Considered in an Exploratory Master Protocol?
- (2020) Cong Chen et al. Statistics in Biopharmaceutical Research
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
- (2019) Susannah L. Hewitt et al. Science Translational Medicine
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
- (2019) Mohammed M. Milhem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
- (2019) Asim Amin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21
- (2019) Nicola E Annels et al. CLINICAL CANCER RESEARCH
- Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma
- (2019) Shailender Bhatia et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Armed oncolytic viruses: A kick-start for anti-tumor immunity
- (2018) J.F. de Graaf et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
- (2018) Dmitriy Zamarin et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
- (2018) Victor H. Engelhard et al. JOURNAL OF IMMUNOLOGY
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
- (2018) Anton Oseledchyk et al. Oncotarget
- Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment
- (2018) David L. Elion et al. Oncotarget
- Talimogene laherparepvec: First in class oncolytic virotherapy
- (2018) Robert M. Conry et al. Human Vaccines & Immunotherapeutics
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
- (2018) Nicola E. Annels et al. Molecular Therapy-Oncolytics
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma.
- (2018) Robert Hans Ingemar Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- LBA16Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors
- (2018) M R Middleton et al. ANNALS OF ONCOLOGY
- LBA45Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
- (2018) K J Harrington et al. ANNALS OF ONCOLOGY
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
- (2018) A Marabelle et al. ANNALS OF ONCOLOGY
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- Application of Cell-free DNA Analysis to Cancer Treatment
- (2018) Ryan B. Corcoran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
- (2018) Heng Zhou et al. Cell Death & Disease
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
- (2017) Georgina V Long et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
- (2017) Alexandra Snyder et al. PLOS MEDICINE
- Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
- (2017) Anna Laurell et al. Journal for ImmunoTherapy of Cancer
- Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
- (2017) et al. Cancers
- Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
- (2016) Peter Ellmark et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The host STING pathway at the interface of cancer and immunity
- (2016) Leticia Corrales et al. JOURNAL OF CLINICAL INVESTIGATION
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The oncolytic peptide LTX-315 triggers immunogenic cell death
- (2016) H Zhou et al. Cell Death & Disease
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety
- (2014) Patricia A. Young et al. SEMINARS IN ONCOLOGY
- Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
- (2014) Linda C Sandin et al. OncoImmunology
- Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials
- (2013) Yuan Ji et al. JOURNAL OF CLINICAL ONCOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunomodulatory cytokines as therapeutic agents for melanoma
- (2011) Courtney Nicholas et al. Immunotherapy
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search